Listing 1 - 2 of 2 |
Sort by
|
Choose an application
Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy. In particular, the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide means that multiple myeloma now stands at the forefront of advances in oncology drug development. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life.
B cells -- Tumors. --- Multiple myeloma. --- Multiple myeloma --- Hemostatic Disorders --- Lymphoproliferative Disorders --- Paraproteinemias --- Neoplasms, Plasma Cell --- Blood Protein Disorders --- Immunoproliferative Disorders --- Vascular Diseases --- Neoplasms by Histologic Type --- Hemorrhagic Disorders --- Hematologic Diseases --- Immune System Diseases --- Cardiovascular Diseases --- Neoplasms --- Hemic and Lymphatic Diseases --- Diseases --- Multiple Myeloma --- Medicine --- Health & Biological Sciences --- Oncology --- Treatment --- B cells --- Tumors. --- B cell neoplasia --- B cell neoplasms --- B cell tumors --- B lymphocyte tumors --- Kahler's disease --- Plasma cell myeloma --- Medicine. --- Cancer research. --- Hematology. --- Oncology. --- Medicine & Public Health. --- Cancer Research. --- Tumors --- Haematology --- Internal medicine --- Blood --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Lymphomas --- Monoclonal gammopathies --- Plasmacytoma --- Oncology .
Choose an application
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Antineoplastic agents. --- Multiple myeloma -- Chemotherapy. --- Multiple myeloma -- Treatment. --- Multiple myeloma --- Antineoplastic agents --- Hemostatic Disorders --- Boron Compounds --- Heterocyclic Compounds, 1-Ring --- Paraproteinemias --- Acids, Noncarboxylic --- Lymphoproliferative Disorders --- Peptide Hydrolases --- Therapeutics --- Therapeutic Uses --- Neoplasms, Plasma Cell --- Enzyme Inhibitors --- Multienzyme Complexes --- Enzymes --- Hydrolases --- Blood Protein Disorders --- Organic Chemicals --- Heterocyclic Compounds --- Acids --- Immunoproliferative Disorders --- Pharmacologic Actions --- Hemorrhagic Disorders --- Multiprotein Complexes --- Vascular Diseases --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Inorganic Chemicals --- Molecular Mechanisms of Pharmacological Action --- Neoplasms by Histologic Type --- Boronic Acids --- Multiple Myeloma --- Antineoplastic Agents --- Drug Therapy --- Proteasome Endopeptidase Complex --- Protease Inhibitors --- Pyrazines --- Chemicals and Drugs --- Immune System Diseases --- Hematologic Diseases --- Macromolecular Substances --- Chemical Actions and Uses --- Cardiovascular Diseases --- Neoplasms --- Enzymes and Coenzymes --- Diseases --- Hemic and Lymphatic Diseases --- Medicine --- Health & Biological Sciences --- Oncology --- Treatment --- Chemotherapy --- Treatment. --- Chemotherapy. --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Kahler's disease --- Plasma cell myeloma --- Medicine. --- Cancer research. --- Pharmacology. --- Oncology. --- Apoptosis. --- Medicine & Public Health. --- Cancer Research. --- Pharmacology/Toxicology. --- Drugs --- Cancer --- B cells --- Monoclonal gammopathies --- Plasmacytoma --- Tumors --- Oncology . --- Toxicology. --- Cytology. --- Cell biology --- Cellular biology --- Biology --- Cells --- Cytologists --- Chemicals --- Pharmacology --- Poisoning --- Poisons --- Toxicology --- Cell death --- Drug effects --- Medical pharmacology --- Medical sciences --- Pharmacy --- Cancer research --- Physiological effect
Listing 1 - 2 of 2 |
Sort by
|